A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of
the Safety, Tolerability and Efficacy of Caveolin-1-ScaffoldingProtein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)
Principal Investigator
Dr Peter Saunders
Contact us
Email: emcrf@ouh.nhs.uk
IRAS number
1011923